Guardian Unlimited
Go to:  
Guardian UnlimitedThe Guardian
Home UK Business Online World dispatch The Wrap Weblog Talk Search
The Guardian World News guide Arts Special reports Columnists Audio Help Quiz

UK news
 
  Search this site








  In this section
Gulf war syndrome: the legal case collapses

UK may tighten benefit controls to deter new EU immigrants

The day the Number 11 bus became a prison for 23 anti-royal protesters

Psychoactive plant qat may join list of banned drugs

Killer was obsessed by porn websites

Never mind the profanities ... here's the apology

Ofsted warns of 'two-tier' curriculum

Soham school wins praise for results

Storms bring flooding chaos

Gallery's u-turn over Marbles

Fuelling violence?

In brief

The homing pigeon's ploy: follow that road

Baby orphaned after mother and sisters murdered and father drowns

Bomb joke Briton seeks deal with cash for 9/11 fund

BBC bosses set to blame it all on 'off-piste' Gilligan

Police hope to bar 2,500 hooligans from Euro 2004

Attempt at human cloning has failed, says fertility doctor

Man did not notice corpse of brother for 18 months

Loophole puts town centres at risk

Inquiry ruling over Asda plan 'critical'

Artist finds peace in Ground Zero

BBC News 24 catches up on Sky

Apology to police for Newsnight interview

Wanted: patients for surgery

Charity highlights peril of real life eviction

European lottery offers Britons 50m jackpot

Fears grow for missing girl


Company 'held back' data on drug for children

Antidepressant had no effect, leak reveals

Sarah Boseley, health editor
Tuesday February 3, 2004
The Guardian


The British manufacturers of an antidepressant drug that was last year banned from use in children knew as long ago as 1998 that it did not work and deliberately avoided publishing the full data because of the risk to their lucrative adult market, according to a leaked internal document.

A position paper dated October 1998 shows that managers at SmithKline Beecham - now GlaxoSmithKline - were concerned at the commercial implications of two clinical trials in which their drug Seroxat was given to children and adolescents with major depression.

The results of both trials, known as protocols 329 and 377, showed that the drug was no better than a placebo - an inert pill - in alleviating the children's depression. An internal unit at the drug company called the Central Medical Affairs team prepared a strategy.

The target, says the document - leaked to the BBC's Panorama team, which has made two programmes on Seroxat - was "to effectively manage the dissemination of these data in order to minimise any potential negative commercial impact". About 500,000 adults were at the time taking the drug in the UK. Seroxat was licensed for their use, but not for use in children. Even so, some 8,000 to 10,000 children were also on it because doctors can prescribe an unlicensed drug on their own responsibility.

The paper says that following consultations within the company, SmithKline Beecham would not submit any data to the regulators to get a statement on the efficacy or the safety of the drug. It says: "It would be commercially unacceptable to include a statement that efficacy had not been demonstrated, as this would undermine the profile of paroxetine [Seroxat]." It adds, however, that "positive data" from the first and bigger study, protocol 329, would be published in abstract form at a psychiatric meeting the following month and that a full manuscript of the trial "will be progressed".

It was eventually published in July 2001 with the conclusion: "Paroxetine is generally well tolerated and effective for major depression in adolescents."

It was only last spring, after Glaxo submitted the full data from protocols 329 and 377, together with a third study of depressed children on Seroxat and data from trials of the drug in children with obsessive compulsive disorder and social anxiety disorder, that the UK regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), realised that not only was Seroxat ineffective in children but that a bigger proportion of those taking it in the trials thought about killing themselves than among those on placebo. The drug was then banned.

Yesterday Alastair Benbow, GSK's head of European clinical psychiatry, said the document "draws inappropriate conclusions and it is inconsistent with the facts".

He insisted that there was no sign of a suicide problem until all the trials were put together.

Richard Brook, the chief executive of Mind, the UK organisation for mental health and a member of the Seroxat review panel convened by the MHRA, said he was appalled by the revelations in the leaked document. To allow the drug to be given to children when there were known side-effects and it could not be proven to work was "morally and ethically bankrupt", he said.

Special reports
Medicine and health

Useful links
British Medical Association
Department of Health
General Medical Council
Health on the Net Foundation
Institute of Cancer Research
Medical Research Council
NHS Direct
World Health Organisation




Printable version | Send it to a friend | Save story

 
 



UP

Guardian Unlimited Guardian Newspapers Limited 2004